FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

October 5, 2026 8:00 AM EDT

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP).

The FDAs Emerging Technology Program, administered within the Agencys Center for Drug Evaluation and Research (CDER), is designed to support the development and implementation of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate the potential to... More